Skip to main content
ESTA logo

ESTA · Establishment Labs Holdings Inc.

Track ESTA — free
$70.75 +2.13 (+3.10%) At close · Nov 13
Market Cap
$2.11B
Shares
29.82M
Volume · Nov 13 367.38K Avg daily vol (3M) 413.73K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$70.75 Open$68.98 Day$67.56–71.58 52W close$54.69–95.65 Avg vol 30d484K Short int3.9M · 13.1% of shares · 6.7d Short vol60% Last earningsOct 29, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 6

Up next

Feb 23, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 36.2% as nine-month loss narrowed

ESTABLISHMENT LABS HOLDINGS INC. reported nine-month revenue of $199.4 million, up 36.2%, while net losses narrowed to $35.8 million from $48.4 million. Cash was $75.8 million as of September 30, 2026, and FDA approved additional smaller Motiva implant sizes.

Revenue $71.99M ▲ 33.9% Net loss $10.71M Diluted EPS -$0.35
Read from the MD&A section
4 source passages
Revenue increased $53.0 million, or 36.2%, to $199.4 million for the nine months ended September 30, 2026 as compared to $146.5 million for the nine months ended September 30, 2025. Net losses were $35.8 million for the nine months ended September 30, 2026 as compared to $48.4 million for the nine months ended September 30, 2025. Our cash balance as of September 30, 2026 was $75.8 million. On the October 5, 2026, the Company announced it received U.S. Food and Drug Administration (“FDA”) approval for additional smaller Motiva implant sizes, expanding the range of options available to U.S. surgeons and patients. Open the document at this passage
Oct 29
Earnings call
Q3 2026 earnings call

Establishment Labs reported third-quarter revenue of $72 million, up 33.9% year-over-year, adjusted EBITDA of $6.4 million and free cash flow of $5.1 million. It raised 2026 revenue guidance to more than $274 million and expects 25% revenue growth in 2027.

Oct 29
Current report 8-K
Financial results

Establishment Labs Holdings Inc. reported third-quarter revenue of $72.0 million, up 33.9%, adjusted EBITDA of $6.4 million and free cash flow of $5.1 million, its first positive quarter; full-year revenue guidance increased to more than $274 million.

Oct 15
Current report 8-K Events of Oct 14
Entered into a material agreement

Establishment Labs Holdings Inc.’s NuSil agreement amendment takes effect January 1, 2027, extending the term from December 31, 2026 to December 31, 2031, with up to five one-year renewals and revised payment, exclusive-supply, continuity and intellectual property provisions.

Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $67.54M ▲ 31.7% Net loss $11.75M Diluted EPS -$0.39
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$264.03M
Trailing 12 months
Net income (TTM)
−$38.45M
Trailing 12 months
Revenue growth YoY
+33.9%
Year over year
Operating margin
-6.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$192.01M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.7%
Year over year · more shares
Price change (1Y)
+9.3%
Trailing year
Short interest
13.1%
Latest settlement · 6.7 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 29, 2026
Q3 FY26

TL;DR. Q3 revenue rose 33.9% to $72.0 million, led by 119.0% U.S. growth; adjusted EBITDA expanded, the company posted its first positive operating and free cash flow, and management raised full-year revenue and minimally invasive revenue guidance. Product approvals and reconstruction progress support growth, but GAAP gross-margin pressure, lower full-year adjusted gross-margin guidance, higher GAAP operating expenses, seasonally lower sequentially minimally invasive revenue, Middle East weakness, and continuing GAAP losses remain headwinds; management expects 25% revenue growth and positive free cash flow in 2027.

Bullish
  • + Q3 revenue increased 33.9% to $72.0 million, driven by 119.0% U.S. growth.
  • + The company generated its first positive quarter of operating cash flow and free cash flow.
  • + Adjusted EBITDA increased to $6.4 million and margin expanded to 8.9% from 2.2%.
  • + Full-year 2026 revenue guidance was raised to more than $274 million from $269 million to $271 million.
Bearish
  • − GAAP gross margin declined to 69.1% from 70.1% in the prior-year quarter.
  • − Minimally invasive revenue declined sequentially because of summer seasonality in OUS direct markets.
  • − The Middle East conflict reduced regional order levels relative to historical performance.
  • − The company remained GAAP unprofitable with a $10.7 million net loss in Q3.
  • − Full-year adjusted gross-margin guidance was lowered to approximately 70.7% from the prior 71.2% to 72.2% range.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −2%
below
Price vs 50-day avg +7%
above
RSI (14) 59
neutral
MACD trend Positive
52-week position 39%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +20%
trailing
6-month return −3%
trailing
YTD return −3%
this year
Relative strength −3%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $66 › 200d $72 — 200d above 50d
Institutional flow Distributing
153 of 198 funds reported for Sep 30 · net -255.3K sh shares · +20 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.14% of shares out · ▼ -2.4% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
198 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Excellent
Revenue growth +76%
Y/Y
Gross margin 239%
contracting
EPS growth +43%
Y/Y
Free cash flow $-56.9M
Balance sheet $90.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 50%
annualized · 1-yr
Max drawdown −39%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 7
Latest guidance · from the 8-K filed Oct 29, 2026
full-year 2026
Revenue at least $274M
prior FY $211.08M midpoint +29.8% Y/Y
Adjusted Gross Margin Non-GAAP Initiated 70.7%
Adjusted Operating Expenses Non-GAAP Initiated $195M – $200M
fiscal 2027
Growth Initiated 25%
Previous outlook earlier release · from the 8-K filed Aug 6, 2026

Still-open targets the latest release did not restate under the same label.

Revenue · full-year 2026 $269M – $271M
Guided vs delivered · last 7 settled
Revenue 2025
guided at least $210M
$211.08M In line
Worldwide revenue 2024
guided $174M – $184M
$166.03M Miss −7.2%
2023 revenue guidance 2023
guided $165M
$165.15M Beat +0.1%
Revenue guidance for 2022 2022
guided $158M – $162M
$161.7M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−2% Neutral
Price vs 50-day avg
+7% Bullish
RSI (14)
59 Neutral
MACD trend
Positive Bullish
52-week position
39% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $66 › 200d $72 — 200d above 50d
Institutional flow Distributing
153 of 198 funds reported for Sep 30 · net -255.3K sh shares · +20 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.14% of shares out · ▼ -2.4% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
198 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $55 Now $71 · 39% Range high $96
vs 200-day avg -2% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $3.7M Q2 2026 —
GAAP → non-GAAP reconciliation
EBITDA -2.32M (the result of another reconciliation in this filing)
+3.14M Stock compensation expense & compensation paid in stock
+697K Foreign currency (gain) loss
+1.86M Third-party debt refinancing costs
+321K Restructuring charges
= Adjusted EBITDA 3.69M
Minimally invasive revenue $12.1M Q2 2026 —
Motiva USA revenue $24.7M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ESTA
Establishment Labs Holdings Inc.
this stock
$2.11B -2.9% +76.5% — 13.1%
ABT
Abbott Laboratories
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
$131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
200
% held
93.3%
Reported
153 of 198
Top holder
RTW INVESTMENTS, LP
Held Float
View
Held by Funds
Fund positions
45
View
Short & Settlement
Short Interest Falling
Shares short
3.9M
Days to cover
6.7d
Change
-98.3K sh
View
Short Volume
Short vol %
60%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
455
Value
$32.5K
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
52.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$211.1M
Net income (FY)
$-51.1M
EPS diluted
$-1.72
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 6, 2026
This year
17

ESTABLISHMENT LABS HOLDINGS INC. reported nine-month revenue of $199.4 million, up 36.2%, while net losses narrowed to $35.8 million from $48.4 million. Cash was $75.8 million as of September 30, 2026, and FDA approved additional smaller Motiva implant sizes.

View
Proposed Sales
Value
$2.0M
Shares
24.2K
Filed
Jun 15, 2026
View
Exempt Offerings
Offering
$50.0M
Filed
Jan 24, 2024
View
Earnings & Events
Webcasts
Last webcast
Oct 29, 2026
View
Investor Relations
Latest news
Establishment Labs® Reports Third…
Published
Oct 29, 2026
View

Performance

5D 20D 120D MTD YTD
ESTA +5.6% +19.6% -2.6% +13.3% -2.9%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +3.0% +20.7% -3.1% +13.5% -13.5%
Key facts CIK 1688757 CUSIP G31249108 13F (30d) 130 filings 124 filers Visit website Investor relations